Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis
-
Published:2022-01
Issue:
Volume:169
Page:103534
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Chierigo FrancescoORCID,
Wenzel Mike,
Würnschimmel ChristophORCID,
Flammia Rocco Simone,
Horlemann BenediktORCID,
Tian Zhe,
Saad Fred,
Chun Felix K.H.,
Tilki Derya,
Shariat Shahrokh F.,
Gallucci Michele,
Borghesi Marco,
Suardi Nazareno,
Terrone Carlo,
Karakiewicz Pierre I.
Subject
Oncology,Hematology
Reference36 articles.
1. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study;Apolo;J. Clin. Oncol.,2017
2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017
3. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017
4. Epidemiology and risk factors of urothelial bladder cancer;Burger;Eur. Urol.,2013
5. Simultaneous comparison of multiple treatments: combining direct and indirect evidence;Caldwell;Br. Med. J.,2005
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献